HOWL — Werewolf Therapeutics Share News
0.000.00%
Last trade - 00:00Werewolf Therapeutics Q4 net loss narrows as expenses fall
Werewolf Therapeutics rises on plans to explore strategic alternatives
NASDAQ RESUMED AT 04:30 PM
NASDAQ RESUMED AT 04:10 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:10 PM
Brief: Werewolf Therapeutics Inc - Plans For Two Inds By Mid-2027
Werewolf Therapeutics Q3 net loss narrows on lower R&D expenses
U.S. STOCKS ON THE MOVE-Datadog, First Majestic, Best Buy
U.S. STOCKS ON THE MOVE-United Rentals, Dell, Datadog
U.S. STOCKS ON THE MOVE-Ford Motor, CVS Health, Phillips 66
Werewolf Therapeutics climbs on FDA's 'fast track' tag for cancer therapy
Brief: Werewolf Therapeutics Receives Fast Track Designation From The U.S. FDA For WTX-124, An Investigational Therapy For The Treatment Of Cancer
Werewolf Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Werewolf Therapeutics Highlights Safety And Efficacy Data From Its Ongoing Phase 1 Clinical Trial
Brief: Werewolf Therapeutics To Present Data From Ongoing Phase 1/1B Clinical Trial Of Wtx-124 As Monotherapy And In Combination With Pembrolizumab In Solid Tumors
Brief: Werewolf Therapeutics Provides Business Update And Highlights 2024 Strategic Outlook
Brief: Adage Capital Partners Reports 8.38% Passive Stake In Werewolf Therapeutics As Of December 11- SEC Filing
Brief: Werewolf Therapeutics Q3 basic EPS USD -0.23
U.S. STOCKS ON THE MOVE-US banks, Cooper-Standard, Udemy